Research Protocols
Standardized experimental protocols and methodological frameworks for peptide research. This guide covers study design, dosing schedules, combination protocols, data collection, and safety monitoring — designed to support reproducible and scientifically valid peptide research.
📋 Introduction
Well-designed research protocols are essential for producing reproducible, interpretable results in peptide research. This guide provides standardized frameworks that can be adapted to specific research questions, experimental models, and regulatory requirements. All protocols assume compliance with institutional animal care and use guidelines, ethics board approval, and appropriate safety precautions.
🔬 Study Design Framework
1. Pre-Study Planning
| Element |
Considerations |
| Research Question |
Specific, measurable, achievable, relevant, time-bound (SMART) |
| Hypothesis |
Null and alternative hypotheses clearly stated |
| Endpoint Selection |
Primary endpoint (power calculation) + secondary endpoints |
| Sample Size |
Power analysis (α = 0.05, β = 0.80 minimum) |
| Control Groups |
Vehicle control, positive control (if applicable), sham |
| Blinding |
Single-blind (investigator) or double-blind (ideal) |
| Randomization |
Computer-generated randomization schedule |
2. Compound Characterization
| Test |
Requirement |
Frequency |
| HPLC Purity |
≥ 95% (≥ 98% preferred) |
Before study start |
| Mass Spectrometry |
Confirm molecular weight |
Lot verification |
| Endotoxin Level |
≤ 5 EU/kg/h (IV); ≤ 0.5 EU/kg/h (intrathecal) |
Each lot |
| Sterility |
USP <71> sterility test |
If > 3 months since manufacturing |
| pH |
5.0–7.0 (most peptides) |
After reconstitution |
| Bioactivity |
Cell-based or in vivo verification |
Initial characterization |
🧪 Standard Dosing Protocol Template
Protocol Design
Peptide: [Name]
Lot Number: [Number]
Purity: [%] (HPLC)
Vehicle: Bacteriostatic water (0.9% benzyl alcohol)
Concentration: [X] mg/mL
Route: [SC/IM/IV/IN/PO]
Dose: [X] μg/kg or [X] mg/subject
Dosing Volume: [X] mL/kg or [X] mL/subject
Frequency: [X] times per [day/week]
Duration: [X] weeks
Washout: [X] weeks (if applicable)
Sample Protocol: Semax in Rodent Cognition Model
| Parameter |
Value |
| Peptide |
Semax (CAS 80714-61-0) |
| Dose |
50 μg/kg (intranasal) |
| Route |
Intranasal (5 μL per nostril) |
| Frequency |
Once daily |
| Duration |
14 days |
| Animals |
Male Wistar rats (200–250 g) |
| Group Size |
n = 10 per group |
| Groups |
Vehicle, Semax 50 μg/kg, Semax 100 μg/kg, Positive control (piracetam 200 mg/kg) |
| Behavioral Tests |
Morris Water Maze (days 8–14), Novel Object Recognition (day 14) |
| Biochemical Endpoints |
BDNF (ELISA), TrkB phosphorylation (Western blot), CREB (pCREB/CREB ratio) |
| Sacrifice |
Day 15; tissue collection (hippocampus, cortex, striatum) |
🔄 Combination Protocol Templates
GHRP-2 + CJC-1295 (Growth Hormone Secretagogue + GHRH Analogue)
| Parameter |
GHRP-2 |
CJC-1295 |
| Dose |
100–300 μg |
1–2 mg |
| Route |
SC |
SC |
| Timing |
2× daily (am + pm) |
Every 5–7 days |
| Cycle |
8–16 weeks |
8–16 weeks |
| Rationale |
Acute GH pulse stimulation |
Sustained GH/IGF-1 elevation |
Protocol Notes
- Administer GHRP-2 immediately before CJC-1295 (synergistic GH release)
- Morning and evening GHRP-2 doses capture natural GH pulse windows
- Monitor IGF-1 levels every 4 weeks
- Contraindicated in subjects with elevated prolactin or cortisol
BPC-157 + TB-500 (Tissue Repair Synergy)
| Parameter |
BPC-157 |
TB-500 |
| Dose |
200–500 μg |
2.5–5 mg |
| Route |
SC around injury site |
SC (systemic) |
| Frequency |
2× daily |
Every 2–3 days |
| Loading Phase |
None |
5–10 mg initial dose |
| Cycle |
4–8 weeks |
4–8 weeks |
Protocol Notes
- BPC-157 administered locally; TB-500 administered at a distal site
- TB-500 loading dose on day 1 (double the maintenance dose)
- Begin protocol within 48 hours of injury induction
- Assess tissue repair via histology, imaging, and functional recovery
Semax + Noopept (Cognitive Enhancement Stack)
| Parameter |
Semax |
Noopept |
| Dose |
200–400 μg |
10–15 mg |
| Route |
Intranasal |
Oral |
| Timing |
Morning |
AM + midday |
| Cycle |
4–8 weeks |
4–8 weeks |
| Washout |
2 weeks |
2 weeks |
Protocol Notes
- Semax provides acute BDNF-mediated cognitive boost
- Noopept provides sustained AMPA receptor facilitation
- Monitor for overstimulation (headache, irritability)
- Reduce doses by 50% if stacking with other nootropics
📊 Data Collection Schedule
Recommended Minimum Data Points
| Timepoint |
Measures |
Notes |
| Day 0 (Baseline) |
Weight, blood work (CBC, CMP), hormone panel |
Full baseline characterization |
| Day 1 |
First dose administered; acute response monitoring |
Vitals at 0, 30, 60, 120 min |
| Weekly |
Weight, food intake, behavioral tests |
Consistent timing each week |
| Mid-cycle |
Blood draw (hormone levels), adverse event review |
Dose adjustment if needed |
| Day 7 post-cycle |
Full blood panel, hormone panel |
Washout start |
| Day 14 post-washout |
Final blood work, endpoint tissue collection |
Terminal procedures |
Hormone Panel Suggestions
| Category |
Analytes |
For Which Peptides |
| Growth Axis |
GH, IGF-1, IGFBP-3 |
MK-677, GHRP-2, GHRP-6, Ipamorelin, CJC-1295, Sermorelin |
| Cortisol/Prolactin |
Cortisol, ACTH, Prolactin |
GHRP-6, GHRP-2 |
| Thyroid |
TSH, T3, T4 |
Metabolic peptides |
| Reproductive |
LH, FSH, Testosterone, Estradiol |
Epitalon, growth peptides |
| Metabolic |
Glucose, Insulin, HbA1c |
GLP-1 agonists, AOD-9604 |
| Inflammatory |
CRP, IL-6, TNF-α |
BPC-157, TB-500 |
⚠️ Safety Monitoring Protocol
Pre-Study
| Check |
Requirement |
| Baseline blood work |
CBC, CMP, coagulation panel |
| ECG |
Cardiac evaluation (for cardiovascular research) |
| Allergy history |
Previous peptide or drug allergies |
| Informed consent |
Approved by institutional IRB |
During Study
| Check |
Frequency |
Action Threshold |
| Weight |
Daily |
> 10% loss → pause protocol |
| Food intake |
Daily |
> 50% reduction × 3 days → pause |
| Injection site |
Daily |
Erythema > 5 cm → document and monitor |
| Behavior |
Weekly |
Abnormal aggression, lethargy, self-harm → halt |
| Blood work |
Every 2 weeks |
Liver enzymes > 3× ULN → halt |
| Vitals |
Weekly |
HR or BP changes > 20% → review |
Adverse Event Grading
| Grade |
Description |
Action |
| 1 (Mild) |
Transient, no intervention needed |
Continue protocol, document |
| 2 (Moderate) |
Symptoms limit activity, minimal intervention |
Continue with increased monitoring |
| 3 (Severe) |
Requires medical intervention |
Pause protocol, provide supportive care |
| 4 (Life-threatening) |
Immediate threat to life |
Halt protocol, emergency intervention |
📈 Statistical Analysis Recommendations
| Endpoint Type |
Statistical Test |
Considerations |
| Continuous (parametric) |
ANOVA + Tukey post-hoc |
Normality (Shapiro-Wilk) and homogeneity (Levene's) |
| Continuous (non-parametric) |
Kruskal-Wallis + Dunn's post-hoc |
For ordinal or non-normal data |
| Repeated measures |
RM-ANOVA or mixed-effects model |
Time × compound interaction |
| Binary outcomes |
Fisher's exact or Chi-square |
Ensure expected cell counts ≥ 5 |
| Survival analysis |
Kaplan-Meier + log-rank |
Censoring considerations |
| Correlation |
Pearson or Spearman |
Linear vs. monotonic relationships |
📚 References
- Guide for the Care and Use of Laboratory Animals — National Research Council, 8th Edition
- Statistical Methods in Biological Research — Nature Methods, 2015
- Peptide Research Protocol Guidelines — Journal of Peptide Science, 2020
- Animal Research: Reporting of In Vivo Experiments (ARRIVE) Guidelines
- Good Laboratory Practice (GLP) Standards — OECD
🔗 AMP Peptide Product Link
Contact AMP Peptide for custom synthesis inquiries